Mirogabalin is a calcium channel blocker with analgesic effects.1 It binds to the α2δ-1 and α2δ-2 subunits of voltage-dependent Ca2+ channels. Mirogabalin has potent and sustained analgesic effects (ED50 = 2.5 mg/kg) in rats with diabetes induced by streptozotocin . Mirogabalin does not inhibit activities associated with CNS adverse effects of analgesics, such as rotarod performance (ID50 = 9.4 mg/kg) or locomotor activity (ID50 = 43.9 mg/kg), at its effective dose.
1.Brown, K., Ohwada, S., Warren, V., et al.(405) A single ascending-dose study of mirogabalin in healthy subjects: Safety, tolerability, pharmacokinetic, and pharmacodynamic results.J. Pain17(4S)S76(2016)